Study Finds Dupilumab Effective for Severe Atopic Dermatitis in Real-world Setting
Dupilumab therapy for 4 weeks in adults with severe atopic dermatitis resulted in significant improvements in clinical outcomes with no adverse events reported.
Dupilumab therapy drove rapid and significant clinical outcomes in patients with severe atopic dermatitis (SAD) in a real world setting, according to a study abstract to be presented at the 2021 American Academy of Allergy, Asthma and Immunology (AAAAI) Virtual Annual Meeting, February 26 – March 1, 2021.
According to researchers from Hospital Universitario de Canarias in Tenerife, Spain, <20% of patients with atopic dermatitis have the severe type but quality of life in this subgroup is markedly disturbed. Led by Paloma Poza Guedes, MD, PhD, the team set out to examine more closely the early effect of dupilumab in a select SAD cohort in a real-world setting.
Participants were adults with SAD; demographics, medical history including comorbidities and medication use were recorded. Values for the following measures were noted prior to starting dupilumab therapy:
- Eczema Area and Severity Index (EASI)
- Scoring AD (SCORAD)
- Validated Global Assessment scale for Atopic Dermatitis (vIGA-AD)
- Pruritus Numerical Rating Scale (PNRS)
- Atopic status (total serum IgE, skin prick test/ImmunoCAP assay, blood eosinophil level)
Outcome data were collected after 4 weeks of treatment (cumulative dupilumab dose, 1200 mg) and included changes in clinical scores and medication use.
Seven patients were included (mean age 27 ± 16.81 yrs) and all reported significant (p<.005) improvement in median clinical scores at 4-week follow-up:
All participants effectively reduced concomitant daily medication for SAD. There were no adverse events reported for dupilumab during the study.
The authors concluded that under real world conditions, treatment with dupilumab resulted in “prompt and significant differences” in clinical outcomes in adult patients with SAD. Clinical safety and efficacy of dupilumab for long-term use will be determined in future studies.
The poster (#008) will be presented at the 2021 AAAAI Virtual Annual Meeting.
